175 related articles for article (PubMed ID: 22226101)
1. Hematopoietic cell transplantation for nonmalignant disorders.
Tolar J; Mehta PA; Walters MC
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S166-71. PubMed ID: 22226101
[TBL] [Abstract][Full Text] [Related]
2. Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies.
Chaudhri NA; Aljurf M; Almohareb FI; Alzahrani HA; Bashir Q; Savani B; Gupta V; Hashmi SK
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):173-177. PubMed ID: 28692818
[TBL] [Abstract][Full Text] [Related]
3. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.
Thakar MS; Broglie L; Logan B; Artz A; Bunin N; Burroughs LM; Fretham C; Jacobsohn DA; Loren AW; Kurtzberg J; Martinez CA; Mineishi S; Nelson AS; Woolfrey A; Pasquini MC; Sorror ML
Blood; 2019 Feb; 133(7):754-762. PubMed ID: 30545834
[TBL] [Abstract][Full Text] [Related]
4. Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes.
Li Q; Luo C; Luo C; Wang J; Li B; Ding L; Chen J
Ann Hematol; 2017 Aug; 96(8):1389-1397. PubMed ID: 28623394
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning (RIC) in children with nonmalignant disorders (NMD) undergoing unrelated donor umbilical cord blood transplantation (UCBT).
Parikh S; Szabolcs P
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S53-5. PubMed ID: 22226113
[No Abstract] [Full Text] [Related]
6. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.
Peffault de Latour R; Peters C; Gibson B; Strahm B; Lankester A; de Heredia CD; Longoni D; Fioredda F; Locatelli F; Yaniv I; Wachowiak J; Donadieu J; Lawitschka A; Bierings M; Wlodarski M; Corbacioglu S; Bonanomi S; Samarasinghe S; Leblanc T; Dufour C; Dalle JH; ;
Bone Marrow Transplant; 2015 Sep; 50(9):1168-72. PubMed ID: 26052913
[TBL] [Abstract][Full Text] [Related]
7. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.
Dietz AC; Mehta PA; Vlachos A; Savage SA; Bresters D; Tolar J; Boulad F; Dalle JH; Bonfim C; de la Fuente J; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP
Biol Blood Marrow Transplant; 2017 May; 23(5):726-735. PubMed ID: 28115275
[TBL] [Abstract][Full Text] [Related]
8. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
Pantin J; Tian X; Shah AA; Kurlander R; Ramos C; Cook L; Khuu H; Stroncek D; Leitman S; Barrett J; Donohue T; Young NS; Geller N; Childs RW
Am J Hematol; 2013 Oct; 88(10):874-82. PubMed ID: 23813900
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group.
Mohamed SY; Fadhil I; Hamladji RM; Hamidieh AA; Fahmy O; Ladeb S; Alimoghaddam K; Elhaddad A; Nacer RA; Alsharif F; Rasheed W; Jahani M; Mousavi SA; Alseraihy A; Abdel-Rahman F; Al Jefri A; Hussein AA; Alabdulaaly A; Ibrahim A; Bekadja MA; Abboud M; Ahmed P; Dennison D; Bakr M; Benchekroun S; Hussain F; Othman TB; Aljurf M; Ghavamzadeh A
Hematol Oncol Stem Cell Ther; 2011; 4(2):81-93. PubMed ID: 21727769
[TBL] [Abstract][Full Text] [Related]
10. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT.
Dietz AC; Savage SA; Vlachos A; Mehta PA; Bresters D; Tolar J; Bonfim C; Dalle JH; de la Fuente J; Skinner R; Boulad F; Duncan CN; Baker KS; Pulsipher MA; Lipton JM; Wagner JE; Alter BP
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1422-1428. PubMed ID: 28533057
[TBL] [Abstract][Full Text] [Related]
11. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.
Lee JL; Lee JH; Lee JH; Choi SJ; Kim S; Seol M; Lee YS; Chi HS; Park CJ; Kim WK; Lee JS; Lee KH
Eur J Haematol; 2003 Aug; 71(2):114-8. PubMed ID: 12890150
[TBL] [Abstract][Full Text] [Related]
13. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
Bhatt ST; Bednarski JJ
Front Immunol; 2020; 11():1988. PubMed ID: 33013851
[TBL] [Abstract][Full Text] [Related]
14. [Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary].
Kállay K; Csomor J; Ádám E; Bödör C; Kassa C; Simon R; Kovács G; Péter G; Ottóffy G; Bartyik K; Kiss C; Masát P; Réti M; Tóth B; Kriván G
Orv Hetil; 2018 Oct; 159(42):1710-1719. PubMed ID: 30334483
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia.
Lee SE; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Lee JW
Eur J Haematol; 2017 Oct; 99(4):336-343. PubMed ID: 28675769
[TBL] [Abstract][Full Text] [Related]
16. Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children.
Andolina JR; Reinish AL; Akhtar R; Noronha S; Shand JC; Girvin A; Korones DN; Bruckner LB; Mullen CA; Curran KJ; Boulad F
Pediatr Blood Cancer; 2018 Aug; 65(8):e27218. PubMed ID: 29722478
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.
Burroughs LM; Shimamura A; Talano JA; Domm JA; Baker KK; Delaney C; Frangoul H; Margolis DA; Baker KS; Nemecek ER; Geddis AE; Sandmaier BM; Deeg HJ; Storb R; Woolfrey AE
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1669-1677. PubMed ID: 28602958
[TBL] [Abstract][Full Text] [Related]
18. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
20. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.
Passweg JR; Baldomero H; Basak GW; Chabannon C; Corbacioglu S; Duarte R; Kuball J; Lankester A; Montoto S; de Latour RP; Snowden JA; Styczynski J; Yakoub-Agha I; Arat M; Mohty M; Kröger N;
Bone Marrow Transplant; 2019 Oct; 54(10):1575-1585. PubMed ID: 30728439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
